Company Encyclopedia
View More
name
Nu Skin
NUS.US
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements.
516.59 B
NUS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Personal Care ProductsIndustry
Industry Ranking8/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE14.55%A
    • Profit Margin7.02%B
    • Gross Margin70.49%A
  • Growth ScoreD
    • Revenue YoY-12.10%E
    • Net Profit YoY206.20%A
    • Total Assets YoY-10.01%E
    • Net Assets YoY13.15%B
  • Cash ScoreC
    • Cash Flow Margin1423.61%B
    • OCF YoY-12.10%E
  • Operating ScoreA
    • Turnover1.04A
  • Debt ScoreC
    • Gearing Ratio43.85%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nu Skin Executive Makes Bold Stock Purchase!

    Nu Skin's Chief Product Officer, Steven Keith Hatchett, purchased 5,500 shares of the company's stock for $52,855, signaling confidence in its future. The company reported strong Q3 growth, particularly in Latin America, and launched the Prysm iO wellness platform. Despite challenges in North America, Nu Skin projects Q4 revenue between $365 million to $400 million. TipRanks' AI Analyst rates NUS as Neutral, highlighting strengths in emerging markets and product innovation, but notes risks from declining revenue and bearish technical indicators.

    Tip Ranks·
    US
    NUS
    -1.70%
    Tip Ranks·
    US
    NUS
    -1.70%

    Nu Skin Chief Product Officer Steven Keith Hatchett Acquires Common Shares

    Steven Keith Hatchett, Chief Product Officer of Nu Skin Enterprises Inc., has acquired common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published by Nu Skin Enterprises Inc. via EDGAR on November 12, 2025.

    Reuters·
    US
    NUS
    -1.70%
    Reuters·
    US
    NUS
    -1.70%

    Nu Skin Enterprises, Inc. to Issue Quarterly Dividend of $0.06 (NYSE:NUS)

    Nu Skin Enterprises, Inc. (NYSE:NUS) has declared a quarterly dividend of $0.06 per share, payable on December 10th to shareholders of record as of November 28th. This represents an annualized yield of 2.6%. The company has a payout ratio of 32.0% and is expected to earn $1.08 per share next year, indicating it can sustain its dividend. The stock recently traded at $9.12, with a market cap of $451.42 million and a P/E ratio of 4.52. Nu Skin's recent earnings report showed an EPS of $0.34, exceeding estimates.

    Market Beat·
    US
    NUS
    -1.70%
    Market Beat·
    US
    NUS
    -1.70%

    Nu Skin Enterprises (NYSE:NUS) Releases Q4 2025 Earnings Guidance

    Nu Skin Enterprises (NYSE:NUS) has updated its Q4 2025 earnings guidance, projecting EPS between 0.250-0.350, slightly below the consensus estimate of 0.330. Revenue guidance is set at $365.0 million-$400.0 million, compared to the consensus of $392.1 million. The company also revised its FY 2025 EPS guidance to 1.250-1.350. Following the announcement, Nu Skin's stock fell by 2.0% to $10.87. Analysts maintain a consensus rating of "Hold" with a price target of $7.00.

    Market Beat·
    US
    NUS
    -1.70%
    Market Beat·
    US
    NUS
    -1.70%

    Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2025 Q3 | NUS Stock News

    Stonegate Capital Partners has updated its coverage on NU Skin Enterprises Inc. (NYSE: NUS) following the company's Q3 2025 results. NU Skin reported revenue of $364.2M, adjusted net income of $17.1M, and adjusted EPS of $0.34, which were below revenue estimates but above EPS expectations. The company achieved a gross margin of 70.5% and reduced selling expenses to 35.8%. Management noted growth in Latin America and plans for a product launch in India in 2026. Cash reserves stand at $251.7M, with guidance for Q4 and full-year 2025 narrowed.

    StockTitan·
    US
    NUS
    -1.70%
    StockTitan·
    US
    NUS
    -1.70%
    © 2025 Longbridge｜Disclaimer